Wistuba, I. I., Futreal, A., Wang, X., Dasari, A., Eng, C., Kopetz, S., . . . Lang, W. (2022). Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). BMJ Publishing Group.
Chicago-čujuhus (17. p.)Wistuba, Ignacio I., et al. Phase II Study of Durvalumab (anti-PD-L1) and Trametinib (MEKi) in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC). BMJ Publishing Group, 2022.
MLA-čujuhus (9. p.)Wistuba, Ignacio I., et al. Phase II Study of Durvalumab (anti-PD-L1) and Trametinib (MEKi) in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC). BMJ Publishing Group, 2022.
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.